NeuroBo Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 12.47 million compared to USD 13.97 million a year ago. Basic loss per share from continuing operations was USD 2.46 compared to USD 43.42 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.075 USD | +1.12% | +7.03% | +11.18% |
09/05 | NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
08/05 | Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.18% | 1.98Cr | |
+4.67% | 11TCr | |
+11.60% | 11TCr | |
-12.86% | 2.23TCr | |
-3.70% | 2.19TCr | |
-6.03% | 1.86TCr | |
-35.21% | 1.81TCr | |
-10.07% | 1.7TCr | |
+3.61% | 1.37TCr | |
+37.96% | 1.24TCr |
- Stock Market
- Equities
- NRBO Stock
- News NeuroBo Pharmaceuticals, Inc.
- NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023